1. [Polymyositis and Jo-1 syndrome].
- Author
-
Treher E, Niederhoff A, Gellissen U, Schmidt P, Dornberg M, and Peter HH
- Subjects
- Adult, Amyloidosis diagnosis, Amyloidosis drug therapy, Amyloidosis immunology, Colchicine administration & dosage, Cyclophosphamide administration & dosage, Diclofenac administration & dosage, Drug Therapy, Combination, Female, Fluorescent Antibody Technique, Histidine-tRNA Ligase immunology, Humans, Methotrexate administration & dosage, Nifedipine administration & dosage, Polymyositis drug therapy, Polymyositis immunology, Prednisolone administration & dosage, Pulmonary Fibrosis diagnosis, Pulmonary Fibrosis drug therapy, Pulmonary Fibrosis immunology, Raynaud Disease diagnosis, Raynaud Disease drug therapy, Raynaud Disease immunology, Syndrome, Antibodies, Antinuclear analysis, Polymyositis diagnosis
- Abstract
Polymyositis is a primarily clinical diagnosis. In 30-40% of patients, however, the specific anti-Jo-1 antibody (anti-histidyl-tRNA-synthetase) can be found. These cases are often associated with interstitial lung disease and other typical clinical manifestations. This symptomatology is called Jo-1-syndrome. Prognosis depends on early diagnosis, since Jo-1 associated interstitial lung disease resulting in pulmonary fibrosis is favorably influenced by immunosuppressive therapy, especially with corticosteroids. The present report concerns a patient with Jo-1-syndrome and beginning pulmonary fibrosis who was treated with methotrexate and prednisolone with good initial response. After 1 year the patient's condition had deteriorated, so that the therapy was changed to cyclophosphamide. Longterm results under this therapy remain to be evaluated.
- Published
- 1993